News Image

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Provided By GlobeNewswire

Last update: Dec 16, 2024

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a global independent investment bank, to identify potential opportunities to enhance shareholder value, including the exploration of strategic partnerships related to its Phase 3-ready program for the treatment of hepatitis C virus (HCV).

Read more at globenewswire.com

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (6/17/2025, 4:30:02 PM)

After market: 3.21 0 (0%)

3.21

+0.02 (+0.63%)



Find more stocks in the Stock Screener

Follow ChartMill for more